<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126220">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113774</url>
  </required_header>
  <id_info>
    <org_study_id>7687</org_study_id>
    <nct_id>NCT02113774</nct_id>
  </id_info>
  <brief_title>The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that antibiotic therapy for asymptomatic bacteriuria in renal
      transplant patients does not have impact on the development of symptomatic urinary tract
      infection (UTI) or progression of renal impairment in patients during the first year after
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>development of symptomatic urinary tract infection</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>25% reduction in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>graft loss</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <condition>Urinary Tract Infection</condition>
  <condition>Bacteriuria</condition>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>no therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>antimicrobial treatment according to in-vitro susceptibility</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>antimicrobial treatment according to in-vitro susceptibility</intervention_name>
    <arm_group_label>antimicrobial treatment according to in-vitro susceptibility</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are ≥1 month and ≤ 12 months after renal transplantation.

          -  Positive urine culture defined as ≥ 105 colony forming units (CFU) per milliliter of
             a known single pathogen.

        Exclusion Criteria:

          -  Any one of the following signs and symptoms: fever, abdominal pain, dysuria,
             frequency, urgency, flank pain, costovertebral-angel tenderness or tenderness over
             the transplanted kidney

          -  Active infections in another site

          -  Leucocytosis (WBC &gt;18.000K/micl) or leucopenia (WBC &lt; 3.000 K/micl)

          -  Elevation of serum creatinine of more than 15% of its baseline level

          -  Obstructive or other urological complications following transplantation as known
             foreign device (stent/double-J-Cath, any catheter) in the urinary tract system, known
             obstruction of the transplanted kidney, indwelling or intermittent catheterization

          -  Pregnant or lactating women.

          -  Candidates to invasive urologic procedures.

          -  Inability to return for regular follow up.

          -  Previous enrollment in this study.

          -  Patients who incapable of giving informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>March 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Ruth Rahamimov</investigator_full_name>
    <investigator_title>head of transplant investigator service</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteriuria</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
